As NASH Treatment Advances to Phase III, Genfit Developing Companion Diagnostic | GenomeWeb

NEW YORK (GenomeWeb) – As part of an upcoming phase III study of its investigational non-alcoholic steatohepatitis (NASH) drug elafibranor, French biopharmaceutical firm Genfit is aiming to validate a diagnostic method that uses blood-based biomarkers to identify patients with the disease who are candidates for treatment.

While the test won't be used to select trial participants, it is expected to launch at the same time as elafibranor and help clinicians know which patients should receive therapy without the need for liver biopsy.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.